Faeth Therapeutics (FTH) Common Equity (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Common Equity came in at -$137.3 million in Q1 2026, down 529.19% YoY from $32.0 million in Q1 2025, and down 838.41% on a QoQ basis from $18.6 million in Q4 2025.
Faeth Therapeutics (FTH) Common Equity (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Common Equity data on file, last reported at -$137.3 million in Q1 2026.
- Quarterly Common Equity fell 529.19% year-over-year to -$137.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$137.3 million (down 529.19% YoY) and the FY2025 annual result came in at $18.6 million, down 51.57% from the prior year.
- Common Equity retreated to -$137.3 million in Q1 2026, from $18.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $135.3 million in Q1 2022 to a low of -$137.3 million in Q1 2026.
- A 5-year average of $55.7 million and a median of $58.5 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity decreased 20.99% — and 2026, when it plunged 529.19%.
- Tracing FTH's Common Equity over 5 years: stood at $103.4 million in 2022, then sank by 37.24% to $64.9 million in 2023, then sank by 40.85% to $38.4 million in 2024, then sank by 51.57% to $18.6 million in 2025, then plunged by 838.41% to -$137.3 million in 2026.
- The last three Common Equity figures came in at -$137.3 million (Q1 2026), $18.6 million (Q4 2025), and $23.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Faeth Therapeutics | 180.89 Mn | 180.89 Mn | - | 172.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 172.96 Mn |
| Mar 31, 2026 | -137.29 Mn |
| Dec 31, 2025 | 18.59 Mn |
| Sep 30, 2025 | 23.01 Mn |
| Jun 30, 2025 | 27.31 Mn |
| Mar 31, 2025 | 31.99 Mn |
| Dec 31, 2024 | 38.39 Mn |
| Sep 30, 2024 | 45.78 Mn |
| Jun 30, 2024 | 52.19 Mn |
| Mar 31, 2024 | 58.47 Mn |
| Dec 31, 2023 | 64.90 Mn |
| Sep 30, 2023 | 71.00 Mn |
| Jun 30, 2023 | 79.20 Mn |
| Mar 31, 2023 | 94.85 Mn |
| Dec 31, 2022 | 103.41 Mn |
| Sep 30, 2022 | 113.99 Mn |
| Jun 30, 2022 | 125.92 Mn |
| Mar 31, 2022 | 135.31 Mn |
| Dec 31, 2021 | 146.51 Mn |
| Sep 30, 2021 | 155.21 Mn |